Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer

被引:6
作者
Mannuel, Heather D.
Hussain, Arif
机构
[1] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA
关键词
external-beam radiation therapy; Gleason score; prostate-specific antigen; radical prostatectomy;
D O I
10.3816/CGC.2006.n.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Locally advanced prostate cancer encompasses several disease states that vary in the risk for progression and recurrence after initial treatment. Further, the optimal treatment strategies for locally advanced prostate cancer are continuing to evolve, reflecting the complex nature of this disease state. For many patients, clinical experience demonstrates that a combined approach of locally directed therapy and systemic therapy is likely to provide better long-term outcome than single-modality therapy. Randomized studies have established hormone ablation with external-beam radiation as an important form of treatment for this group of patients. However, additional progress needs to be made, particularly in the subgroup of patients with very high-risk disease features. As the optimal integration of local and systemic treatments becomes more clearly defined, the long-term prognosis for patients with high-risk locally advanced prostate cancer will improve.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 50 条
  • [31] High-risk localized prostate cancer: Integrating chemotherapy
    Oh, WK
    ONCOLOGIST, 2005, 10 : 18 - 22
  • [32] Current role of surgery for high risk prostate cancer
    Joniau, Steven
    Van der Eeckt, Kathy
    Briganti, Alberto
    Gontero, Paolo
    Van Bruwaene, Siska
    Karnes, R. Jeffrey
    Spahn, Martin
    Van Poppel, Hein
    ARCHIVOS ESPANOLES DE UROLOGIA, 2013, 66 (03): : 259 - 274
  • [33] What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?
    Namiki, Mikio
    Konaka, Hiroyuki
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (04) : 624 - 625
  • [34] Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
    Morgan, Scott C.
    Dearnaley, David P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 939 - 951
  • [35] Adjuvant Therapy in High-Risk Prostate Cancer
    Shevach, Jeffrey
    Chaudhuri, Parul
    Morgans, Alicia K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 45 - 53
  • [36] The role for surgeryin high-risk prostate cancer
    Lanchon, Cecilia
    Shariat, Shahrokh F.
    Roupret, Morgan
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (19-20) : 395 - 400
  • [37] Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation
    Ludgate, CM
    Bishop, DC
    Pai, H
    Eldridge, B
    Lim, J
    Berthelet, E
    Blood, P
    Piercy, GB
    Steinhoff, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (05): : 1309 - 1315
  • [38] High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation
    Molitoris, Jason K.
    Alexander, Gregory S.
    Siddiqui, Osman
    Cohen, Justin
    Mishra, Mark, V
    Rana, Zaker
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (03) : 238 - 243
  • [39] Optimization of the Radiation Management of High-Risk Prostate Cancer
    Nguyen, Paul L.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (01) : 43 - 49
  • [40] Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer
    Fletcher, Sophie G.
    Mills, Stacey E.
    Smolkin, Mark E.
    Theodorescu, Dan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (04): : 1092 - 1099